一、募集资金基本情况 （一）募集资金金额及到位时间 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2020 年 8 月 4 日出具的《关于同意北京莱伯泰科仪器股份有限公司首次公开发行股票注册的批 复》（证监许可[2020]1657 号），公司获准向社会公开发行人民币普通股 1,700 万 股，每股发行价格为 24.80 元，募集资金总额为 421,600,000.00 元，扣除各项发行 费用（不含增值税）人民币 47,117,924.53 元，实际募集资金净额为人民币 374,482,075.47 元。上述资金已全部到位，经信永中和会计师事务所（特殊普通 合伙） 审验 并出 具 《北京 莱伯 泰科 仪 器股份 有限 公司 验 资报告 》（ 编号 XYZH/2020BJA20751）。上述募集资金到账后，已全部存放于公司董事会同意开 立的募集资金专项账户内，并由公司与保荐机构、存放募集资金的商业银行签署 了三方监管协议。 关于北京莱伯泰科仪器股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为北京莱 伯泰科仪器股份有限公司（以 ...

北京莱伯泰科仪器股份有限公司 2023 年度董事会审计委员会履职情况报告 2023 年度，北京莱伯泰科仪器股份有限公司（以下简称"公司"或"莱伯泰 科"）董事会审计委员会根据《上市公司治理准则》、《上海证券交易所科创板股 票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等法律法规、规范性文件，以及《公司章程》、《公司董事会审计委员会工作 细则》的有关规定，本着勤勉尽责的原则，积极开展各项工作，现将董事会审计 委员会在 2023 年度的履职情况汇报如下： 一、审计委员会的基本情况 | 序号 | | 时间 | | 会议届次 | 审议议案 | 审议人员 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 年 2023 | 月 4 | 日 23 | 审计委员会 2023 | 1、关于公司《2022 年年度报告》及其摘 要的议案； 2、关于公司《2023 年第一季度报告》的 议案； 3、关于公司《2022 年度董事会审计委员 会履职情况报告》的议案； 年度财务决算报告的议 4、关于公司 2022 | 郑建明、孔 | | | | | | ...

| 索引 | 页码 | | --- | --- | | 鉴证报告 | 1-2 | | 关于募集资金 2023 年度存放与使用情况的专项报告 | 1-16 | 北京莱伯泰科仪器股份有限公司 2023 年度 募集资金年度存放与使用情况鉴证报告 信永中和会计师事务所 | 北京市东城区朝阳门北大街 | 8 号富华大厦 A 座 9 层 联系申话: telephone: +86 (010) 6554 2288 ShineWing certified public accountants 9/F Block A. Fu Hua Mansion No 8 Chaovangmen Beidaiie Donachena District, Beijing 100027. P.R.China 86 (010) 6554 7190 募集资金年度存放与使用情况鉴证报告 XYZH/2024BJAA2F0113 北京莱伯泰科仪器股份有限公司 北京莱伯泰科仪器股份有限公司全体股东: 我们对后附的北京莱伯泰科仪器股份有限公司(以下简称莱伯泰科公司)关于募集 资金 2023 年度存放与使用情况的专项报告（以下简称募集资金年度存放与使用情况专 项 ...

招商证券股份有限公司 关于北京莱伯泰科仪器股份有限公司 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 北京莱伯泰科仪器股份有限公司于 2024 年 4 月 25 日召开第四届董事会第十 二次会议、第四届监事会第十一次会议，审议通过了《关于预计公司 2024 年度 日常关联交易的议案》，本次日常关联交易预计金额合计为 34,780.00 元人民币。 出席会议的非关联董事一致同意该议案，审议程序符合相关法律法规的规定。本 次日常关联交易额度预计事项无需提交股东大会审议。 公司第四届董事会独立董事专门会议第一次会议审议通过了《关于预计公司 2024 年度日常关联交易的议案》。独立董事认为：公司在 2024 年与关联方已经 发生的关联交易及预计将要发生的关联交易均为公司正常经营业务所需，属正常 商业行为，遵守了自愿、等价、有偿的原则，定价公平合理，并已按照公司的章 程及决策程序履行了相关审批程序，所发生的关联交易符合公司的利益，不存在 损害公司和其他股东利益的情况。本次董事会审议公司 2024 年度关联交易事项 时，关联董事均回避表决，决策程序符合有关法律法规和公司章程的规定。 公司董事会审计委员会审议 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2024-022 北京莱伯泰科仪器股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 17 日 14 点 00 分 召开地点：北京市顺义区空港工业区 B 区安庆大街 6 号北京莱伯泰科仪器股 份有限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 17 日 至 2024 年 5 月 17 日 股东大会召开日期：2024年5月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易 ...

公司代码：688056 公司简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2023 年度内部控制评价报告 北京莱伯泰科仪器股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的 ...

Financial Performance - In 2023, the company's operating revenue reached RMB 415.995 million, an increase of 17.18% compared to RMB 355.005 million in 2022[19]. - The net profit attributable to shareholders decreased by 38.23% to RMB 27.5625 million from RMB 44.6245 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 23.3012 million, down 43.41% from RMB 41.1749 million in 2022[20]. - The gross profit margin for all products was 43.79%, a decrease of 3.92 percentage points compared to the previous year[22]. - Operating costs amounted to 233.826 million yuan, reflecting a year-on-year increase of 25.96%[32]. - Basic earnings per share were 0.41 yuan, down 38.81% year-on-year, while diluted earnings per share were also 0.41 yuan[32]. - The company's total assets increased by 4.47% to RMB 1,004.498 million at the end of 2023, compared to RMB 961.5294 million at the end of 2022[20]. - The weighted average return on net assets was 3.29%, down 2.26 percentage points from 5.55% in 2022[21]. - The net cash flow from operating activities was RMB 42.5987 million, a significant increase from RMB 7.594 million in the previous year[20]. Research and Development - Research and development expenses accounted for 12.55% of operating revenue, an increase of 1.73 percentage points from 10.82% in 2022[21]. - The company achieved a total R&D investment of 52.22 million yuan, representing a 35.97% increase compared to the previous year, with an increase of 13.82 million yuan[89]. - The total R&D investment accounted for 12.55% of operating revenue, up from 10.82% in the previous year, marking an increase of 1.73 percentage points[89]. - The company has established a research and development team of 142 personnel, with R&D staff accounting for 25.63% of the total workforce, an increase from 23.81% in the previous period[100]. - The average salary of R&D personnel increased to 24.07万元 from 21.16万元, reflecting the company's investment in talent[100]. Product Development and Innovation - The company launched new products including full-spectrum direct reading inductively coupled plasma spectrometers and gas chromatography-single quadrupole mass spectrometry instruments[34]. - The company launched the LabMS 5000 ICP-MS/MS on March 10, 2023, targeting the semiconductor industry with enhanced sensitivity and lower detection limits[35]. - The company developed a complete sample pretreatment and detection method for new pollutants, including several automated pretreatment instruments[37]. - The company has introduced advanced products such as the fully automated solid-phase extraction system and high-throughput pressure extraction instruments, enhancing its product offerings[52]. - The company is focusing on the development of new technologies and products to meet the strong domestic demand in the semiconductor and medical fields[94]. Market and Sales - The company has established a broad sales network, with subsidiaries in the US and Hong Kong, and products sold in multiple countries and regions[41]. - The company aims to enhance instrument performance and analysis technology to improve detection accuracy and efficiency, addressing food safety and pollution issues[44]. - The company is expanding its market presence in environmental protection, food safety, and pharmaceutical industries through innovative product development and strategic investments[93]. - The company has established subsidiaries in the US and Hong Kong to expand its overseas business, but faces challenges due to trade disputes and regulatory changes[112]. - The company is exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[190]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company has received a standard unqualified audit report from Xinyong Zhonghe Accounting Firm[5]. - The company has maintained compliance with legal regulations and corporate governance standards throughout the reporting period[186]. - The company continues to innovate and improve its internal control systems, ensuring compliance with relevant laws and regulations to protect investor rights[46]. Awards and Recognition - The company has received multiple awards, including the BCEIA Gold Award for its products and recognition as a leading enterprise in the scientific instrument industry[48]. - The company was recognized as a "National Specialized and New 'Little Giant' Enterprise" in 2022, highlighting its innovation capabilities[84]. - The company received multiple awards for its products, including the BCEIA Gold Award for the D-Master automatic digestion instrument and the LabMS 5000 ICP-MS/MS, indicating strong market recognition[103]. Future Outlook - The company plans to continue expanding into new industries, which is expected to drive future revenue growth[145]. - The company aims to enhance its overall solution capabilities and one-stop procurement for laboratory analysis instruments[174]. - The company has set ambitious performance guidance for the next fiscal year, aiming for a revenue growth rate of over 15%[191]. - The management team emphasizes the importance of maintaining high standards in research and development to drive future growth[190]. - The company plans to allocate surplus funds from its initial public offering to new projects and to permanently supplement working capital[186].

Financial Performance - The company's operating revenue for Q1 2024 was ¥105,478,954.63, representing a year-on-year increase of 9.19%[4] - The net profit attributable to shareholders decreased by 10.05% to ¥11,574,778.68 compared to the same period last year[4] - The basic earnings per share (EPS) was ¥0.17, reflecting a decrease of 10.53% compared to the previous year[4] - Net profit for Q1 2024 was ¥11,574,778.68, a decrease of 10.0% from ¥12,867,741.35 in Q1 2023[22] - The company reported a basic earnings per share of ¥0.17 for Q1 2024, down from ¥0.19 in Q1 2023[23] Research and Development - Research and development expenses totaled ¥12,347,788.06, accounting for 11.71% of operating revenue, an increase of 1.36 percentage points year-on-year[4] - Research and development expenses increased to ¥12,347,788.06 in Q1 2024, compared to ¥10,000,621.08 in Q1 2023, marking a growth of 23.5%[22] Cash Flow - The net cash flow from operating activities was negative at -¥1,282,305.88, indicating a cash outflow during the quarter[4] - Cash flow from operating activities showed a net outflow of ¥1,282,305.88 in Q1 2024, an improvement from a net outflow of ¥9,963,786.03 in Q1 2023[25] - The net cash flow from investing activities was -$140,634,112.25, a significant decrease compared to $26,657,534.86 in the previous period[26] - The total cash and cash equivalents at the end of the period amounted to $312,429,134.15, down from $386,275,431.70 in the prior year[26] - The net increase in cash and cash equivalents was -$152,306,760.90, contrasting with an increase of $15,446,954.30 in the previous period[26] - Cash outflows from financing activities totaled $10,190,048.43, compared to $156,559.38 in the prior year[26] - The impact of exchange rate changes on cash and cash equivalents was -$200,294.34, compared to -$1,090,235.15 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥989,709,737.18, a decrease of 1.47% from the end of the previous year[5] - As of March 31, 2024, the total assets of the company amounted to ¥989,709,737.18, a decrease from ¥1,004,497,965.18 as of December 31, 2023, reflecting a decline of approximately 1.8%[18] - The company's cash and cash equivalents decreased to ¥321,141,246.28 from ¥472,914,097.10, representing a decline of about 32.1%[15] - The total current assets were reported at ¥783,510,899.11, down from ¥797,748,505.14, indicating a decrease of approximately 1.8%[17] - Total liabilities decreased to ¥137,230,964.54 in Q1 2024 from ¥155,174,803.34 in Q1 2023, a reduction of 11.6%[19] - The total current liabilities decreased to ¥128,227,004.47 from ¥148,366,244.34, reflecting a decline of about 13.6%[18] - The company's non-current assets totaled ¥206,198,838.07, a slight decrease from ¥206,749,460.04, indicating a decline of approximately 0.3%[18] - The company reported a significant reduction in contract liabilities from ¥74,466,404.19 to ¥60,689,040.75, a decrease of approximately 18.5%[18] - The deferred income tax assets increased to ¥5,906,816.59 from ¥4,956,879.45, reflecting an increase of about 19.2%[18] Government Subsidies and Gains - The company received government subsidies amounting to ¥70,208.88, which are closely related to its normal business operations[6] - The total non-recurring gains and losses amounted to ¥1,158,418.08 after tax adjustments[7] Operating Costs - Total operating costs for Q1 2024 were ¥95,653,559.54, up from ¥85,415,435.68 in Q1 2023, reflecting a rise of 12.5%[21]

关于北京莱伯泰科仪器股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：北京莱伯泰科仪器股份有限公司全体股东 审计单位：信永中和会计师事务所(特殊普通合伙) 联系电话：010-80492709 北京莱伯泰科仪器股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1 | 北京市东城区朝阳门北大街 菲桑申话: 信永中知会计师事务近 +86 (040) R664 2288 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 ShineWing certified public accountants 关于北京莱伯泰科仪器股份有限公司 2023 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2024BJAA2F0112 北京莱伯泰科仪器股份有限公司 我们按照中国注册会计师审计准则审计了北京莱伯泰科仪器股份有限公司(以下简 称莱伯泰 ...

北京莱伯泰科仪器股份有限公司 2023 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-4 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | ୧ | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-84 | 信永中和会计师事务所 | 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 ertified public accountants 9/F. Block A. Fu Hua Mansion No 8 Chaovangmen Reidaile Donachena District, Beijing 100027. P.R.China +86 (010) 6554 7190 审计报告 XYZH/2024BJAA2B0230 北京莱伯泰科仪器股份有限公司 北京莱伯泰科仪器股份有限公司全体股东: 一、审计意见 联系由话 +86 ( ...